Influx Healthtech Share Price Surges 38% on NSE Emerge Debut – A Strong Listing for SME IPO

Market Debut: Influx Healthtech Lists with 38% Premium

Influx Healthtech made a striking debut on the NSE Emerge platform on June 25, with its shares listing at ₹132.50 apiece.

• IPO Price: ₹96 per share
• Listing Price: ₹132.50
• Listing Gain: Over 38% premium on the issue price

The premium was significantly higher than grey market expectations, which had pegged the stock around ₹116, implying a 21% gain before listing.

Main News: Influx Healthtech’s IPO Sees Exceptional Response

Influx Healthtech’s SME IPO witnessed robust investor enthusiasm.

• Subscription Level: 187.32 times
• Bidding Period: June 18 to June 20
• Grey Market Premium (Pre-Listing): ₹116

This surge in interest highlights the market’s current appetite for healthcare and tech-based SME offerings.

Company Details: Healthcare Focused Influx Healthtech

Influx Healthtech, headquartered in Mumbai, operates primarily in the healthcare sector. The company focuses on developing and distributing:

• Nutraceutical products
• Veterinary food solutions
• Homecare and cosmetic products

The strong debut reflects growing investor interest in niche, healthcare-oriented companies that tap the SME segment.

Financial Snapshot of the IPO

The IPO aimed to raise capital primarily for infrastructure development and operational enhancement.

IPO Fund Utilization Breakdown

• Total Funds Raised: ~₹59 Crore
• Price Band: ₹91 – ₹96 per share
• Minimum Lot Size: 1,200 shares
• Minimum Investment Required: ₹1.15 lakh

Use of Proceeds:

• Setting up manufacturing facilities for:
  • Nutraceutical division
  • Veterinary food division
• Machinery procurement for:
  • Homecare segment
  • Cosmetic division
• General corporate purposes

Summary of the Article

The Influx Healthtech share price listing on NSE Emerge impressed with a 38% gain over the IPO price, outperforming the market and grey market expectations. Backed by high investor demand—evident from a 187.32x subscription rate—the IPO successfully raised ₹59 Crore for expanding its production capabilities across multiple healthcare verticals. The company’s future trajectory in the SME segment will be closely watched by investors tracking healthcare-focused opportunities.